We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 03 NOVEMBER 2009
IP Update - October, 2009
McDermott Will & Emery
The U.S. Court of Appeals for the Federal Circuit invalidated claims for a method of treating Alzheimer’s disease because the specification comprised a summary of six scientific papers and reported no data on the use of the compound at issue in humans.
United StatesIntellectual Property





